Nonclinical Toxicology Strategy

Nonclinical toxicology strategy characterizes dose-related toxicity, target organs, reversibility, and safety margins that justify human exposure. Study design choices (species, duration, endpoints, recovery arms) either answer regulatory questions efficiently or create a trail of repeat work. Toxicology is also where programs learn which findings are manageable and which reshape the clinical plan, so interpretation quality matters as much as study execution.

Viltis helps sponsors build toxicology plans aligned to ICH expectations and the specific modality, including small molecules, biologics, and advanced therapies where standard packages need thoughtful adaptation. We support IND-enabling packages, interpretation of histopathology and clinical pathology signals, and dose selection logic for first-in-human studies. When findings are complex, we help frame risk communication for clinical, regulatory, and governance teams without overstating or burying the issue. Timing relative to clinical milestones stays explicit so toxicology does not become the silent critical path.

Specialized studies (safety pharmacology, genotoxicity, reproductive toxicology, or modality-specific packages) need early sequencing so they do not become last-minute blockers. We help sponsors map those requirements to indication and region, and we challenge redundant testing that does not change risk management. The aim is an efficient package that still answers the questions reviewers will ask. We keep species selection and study duration decisions written down so later teams inherit the logic, not only the reports.

Toxicology strategy work commonly includes

• IND-enabling toxicology package design
• Species and study duration rationale
• Interpretation of target organ findings
• Safety margin and starting dose support
• Recovery and specialized study planning
• CRO toxicology oversight and data review
• Integration with clinical risk mitigation plans

A useful toxicology strategy is specific: which studies, in what order, and what decision each result must support. Viltis keeps that thread intact from protocol to interpretation so safety data serve development instead of sitting as unread PDF binders. When unexpected toxicity appears, we help the team decide quickly whether to deepen the nonclinical package, adjust clinical monitoring, or revisit the candidate. If a toxicology finding is driving clinical anxiety, we help quantify margins, monitoring options, and the minimum additional work needed to decide go or no-go.